XL FUS BA consists of an orange-labeled probe hybridizing proximal to the FUS gene region at 16p11.2 and a green-labeled probe hybridizing distal to the FUS gene region at 16p11.2.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Myxoid liposarcomas (MLS) are accounting for about 30% of liposarcomas and represent approximately 10% of adult soft tissue sarcomas. Patients with MLS showing progression to round-cell morphology have an inferior outcome. The most common aberration in MLS is the translocation t(12;16)(q13;p11) with a frequency of about 95% and to a much lesser extend t(12;22)(q13;q12), in which FUS is not involved. These reciprocal translocations are resulting in the generation of FUS-DDIT3 and EWSR1-DDIT3 fusion genes, respectively. As FUS is also involved in the development of low-grade fibromyxoid sarcoma with the rearrangement t(7;16)(q33;p11), FUS rearrangements are not highly specific for the detection of MLS. Human models of sarcomagenesis suggest that the FUS-DDIT3 fusion gene impedes with adipogenic differentiation of mesenchymal stem cells and thereby contributes to the development of liposarcoma.

Clinical Applications

• Solid Tumors (Solid Tumors)

XL FUS BA hybridized to a tissue specimen, several aberrant cells are shown.

• Knight et al (1995) Cancer Res 55:24-27
• Tanas et al (2009) Adv Anat Pathol 16:383-391
• Rodriguez et al (2013) Stem Cells 31:2061-2072